By Lara C. Pullen, PhD CLICK TO VIEW ARTICLE > Rheumatologists lack a definitive diagnostic tool to determine whether a patient has systemic lupus erythematous (SLE) and/or when a patient will...
Les Sinclair talks with Dr. Amrie Grammer about AMPEL BioSolutions, a Charlottesville Virginia company that has reengineered the gene-based technology they developed for lupus to COVID19.
Peter E. Lipsky, MD, Co-Founder and Chief Executive Officer of AMPEL BioSolutions, Charlottesville, VA, works to change that, and he will discuss his efforts during the Clinical Science symposium Mining Big Data for Drug Repurposing.